Risk of febrile neutropenia and early treatment cessation in men receiving standard and dose ‐reduced 3‐weekly docetaxel for metastatic castration‐resistant prostate cancer

Asia-Pacific Journal of Clinical Oncology, EarlyView.

Source: Asia-Pacific Journal of Clinical Oncology - January 10, 2018 Category: Cancer & Oncology Source Type: research